ArticleJournal of medicinal chemistry2016
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.
Open access · greenAbstract read
In one paragraph
Article in Journal of medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- The translational potential of salvinorin A: systematic review and meta-analysis of preclinical studies.Translational psychiatry · 2025Pooled it
- Barettin, a Nonopioid, Nonhallucinogenic Marine Natural Product with Antihyperalgesic Properties Mediated by 5HT2A Inverse Agonism.Journal of natural products · 2026Article
- N-(3-Hydroxyphenyl)-3,8-diazabicyclooctanes as opioid receptors probes. 1. Investigation of the phenolic hydroxyl group.European journal of medicinal chemistry · 2025Article
- Role of β-Arrestin 2 in the antinociceptive and side effect profile of morphine and the novel mu opioid receptor agonists, kurkinorin and kurkinol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Semi-synthesis in the exploration of opioid-targeting natural products.Natural product reports · 2025Review
- Searching for Synthetic Opioid Rescue Agents. 2: Identification of an Ultra-Potent Synthetic Opioid Rescue Agent.Journal of medicinal chemistry · 2025Article
- Emerging Psychotropic Drug for the Treatment of Trigeminal Pain: Salvinorin A.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.Journal of medicinal chemistry · 2024Article
- From Plant to Chemistry: Sources of Active Opioid Antinociceptive Principles for Medicinal Chemistry and Drug Design.Molecules (Basel, Switzerland) · 2023Review
- Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans.Molecules (Basel, Switzerland) · 2023Article
- Modified Akuamma Alkaloids with Increased Potency at the Mu-opioid Receptor.Journal of medicinal chemistry · 2023Article
- Solving an Old Puzzle: Elucidation and Evaluation of the Binding Mode of Salvinorin A at the Kappa Opioid Receptor.Molecules (Basel, Switzerland) · 2023Article
- Metadynamics simulations leveraged by statistical analyses and artificial intelligence-based tools to inform the discovery of G protein-coupled receptor ligands.Frontiers in endocrinology · 2022Review
- Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent.Journal of biomedical science · 2021Article
- Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.RSC medicinal chemistry · 2021Review
- Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.Biochemistry · 2021Review
- The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.Neuropharmacology · 2021Article
- The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis.Frontiers in neurology · 2021Article
- Biased Opioid Ligands.Molecules (Basel, Switzerland) · 2020Review
- How Do Molecular Dynamics Data Complement Static Structural Data of GPCRs.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Rachel Saylor CrowleyDepartment of Medicinal Chemistry, School of Pharmacy, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott, Lawrence, Kansas 66045, United States.
Andrew P RileyDepartment of Chemistry, The University of Kansas , Lawrence, Kansas 66045, United States.
Alexander M SherwoodDepartment of Medicinal Chemistry, School of Pharmacy, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott, Lawrence, Kansas 66045, United States.
Chad E GroerDepartment of Medicinal Chemistry, School of Pharmacy, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott, Lawrence, Kansas 66045, United States.
Nirajmohan ShivaperumalCentre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington , Wellington 6140, New Zealand.
Miguel BiscaiaCentre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington , Wellington 6140, New Zealand.
Kelly PatonCentre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington , Wellington 6140, New Zealand.
Sebastian SchneiderDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States.
Davide ProvasiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States.
Bronwyn M KivellCentre for Biodiscovery, School of Biological Sciences, Victoria University of Wellington , Wellington 6140, New Zealand.
Marta FilizolaDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States.ORCID 0000-0002-4382-8276
Thomas E PrisinzanoDepartment of Medicinal Chemistry, School of Pharmacy, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott, Lawrence, Kansas 66045, United States.ORCID 0000-0002-0649-8052
University of Kansas · USVictoria University of Wellington · NZIcahn School of Medicine at Mount Sinai · US
Funding
Investigation of Neoclerodanes as Novel Opioid LigandsR01DA018151 · NIDA · UNIVERSITY OF KENTUCKY · PI PRISINZANO, THOMAS EDWARD · 2005 to 2020
$5.7MTRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9MTransforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9MDynamic Mechanisms of GPCRs Targeted by Drugs of AbuseR01DA034049 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FILIZOLA, MARTA · 2012 to 2016
$1.8MLegacy continuation of the KU CMLD MissionR24GM111385 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI PRISINZANO, THOMAS EDWARD · 2014 to 2016
$1.5MStructural Aspects of Oligomerization in the Function of GPCRsK02DA026434 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FILIZOLA, MARTA · 2009 to 2018
$1.2MAvance II 500 High Performance Digital NMR Spectrometer SystemS10RR024664 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI VANDERVELDE, DAVID G · 2007 to 2007
$468kEnhanced Molecular Dynamics Methods to Investigate GPCR Ligand BindingR21MH107053 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FILIZOLA, MARTA · 2016 to 2017
$466kNCRR NIH HHS S10 RR024664NIDA NIH HHS K02 DA026434NIDA NIH HHS R01 DA018151NIDA NIH HHS R01 DA034049NIGMS NIH HHS R24 GM111385NIGMS NIH HHS T32 GM008545NIH HHS S10 OD018522NIMH NIH HHS R21 MH107053
Abstract
Opioids are widely used to treat millions suffering from pain, but their analgesic utility is limited due to associated side effects. Herein we report the development and evaluation of a chemical probe exhibiting analgesia and reduced opioid-induced side effects. This compound, kurkinorin (5), is a potent and selective μ-opioid receptor (MOR) agonist (EC
Indexed as
Analgesics, OpioidAnimalsCells, CulturedCHO CellsCricetulusDiterpenesDiterpenes, ClerodaneDose-Response Relationship, DrugMaleMolecular StructurePainPain MeasurementRatsRats, Sprague-DawleyReceptors, Opioid, muSalviaAnalgesics, OpioidDiterpenesDiterpenes, ClerodaneneoclerodaneReceptors, Opioid, mu
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.